- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05242042
JT001 (VV116) for the Early Treatment of COVID-19
A Multicenter, Double-blind, Randomized, Placebo-Controlled, Phase II/III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of JT001 (VV116) for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Participants With Mild to Moderate COVID-19.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Screening Interested participants will sign the appropriate informed consent form (ICF) prior to completion of any study procedures.
The investigator will review symptoms, risk factors and other non-invasive inclusion and exclusion criteria prior to any invasive procedures. If the participant is eligible after this review, then the site will perform the invasive procedures to confirm eligibility.
Treatment and Assessment Period
- Complete baseline procedures and sample collection
- Participants are randomized to an intervention group
- Participants receive study intervention (Q12H X 5 days)
- Complete all safety monitoring
- Complete all efficacy data collection
- Blood samples collection
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Jie Wang, Project Manager
- Phone Number: 8618036618073
- Email: jie_wang5@junshipharma.com
Study Contact Backup
- Name: Yali Pan, Project Directer
- Phone Number: 8618621590299
- Email: yali_pan@junshipharma.com
Study Locations
-
-
Chongqing
-
Chongqing, Chongqing, China
- Chongqing Public Health Medical Center
-
-
Henan
-
Zhengzhou, Henan, China
- Thesixth peoples Hospital Of ZhengZhou
-
-
Jiangsu
-
Wuxi, Jiangsu, China
- Wuxi No.5 People's Hospital
-
-
Jiangxi
-
Nanchang, Jiangxi, China
- The Ninth Hospital of Nanchang
-
-
Liaoning
-
Shenyang, Liaoning, China
- The Sixth People's Hospital of Shenyang
-
-
Shanghai
-
Shanghai, Shanghai, China, 201508
- Shanghai Public Health Clinical Center
-
-
-
-
-
Hongkong, Hong Kong
- CUHK Medical Centre
-
Hongkong, Hong Kong
- CUHK Phase 1 Clinical Trial Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants of 18 years of age or older
- Participants who have a positive SARS-CoV-2 test result, and have sample collection for first positive SARS-CoV-2 viral infection determination ≤5 days prior to randomization
- Participants who have one or more mild or moderate COVID-19 symptoms as follows and have a COVID-19 Related Symptom score ≥3
- Participants with the onset of symptoms of COVID-19 ≤5 days prior to randomization
- Participants who satisfy one or more than one of the following high risks for progression to severe COVID-19, including death:
- Participants who must agree to adhere to contraception restrictions
- Participants who understand and agree to comply with planned study procedures
- Participants can give written informed consent approved by the Ethical Review Board governing the site and comply with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
Exclusion Criteria:
- Participants who are judged by the investigator as likely to progress to severe/critical COVID-19 prior to randomization.
- Participants who have SpO2≤93% on room air at sea level or PaO2/FiO2≤ 300, or respiratory rate ≥30 per minute, or heart rate ≥125 per minute
- Participants who require mechanical ventilation or anticipated impending need for mechanical ventilation
- Participants who are suspected or proven serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking intervention
- Participants who have eye disease
- Participants who have ALT or AST>2 ULN at screening
7 Participants who have known allergies to any of the components used in the formulation of the interventions
8 Any medical condition, which in the opinion of the Investigator, will compromise the safety of the participant
9. Participants who have received a SARS-CoV-2 monoclonal antibody treatment or prevention, or antiviral treatment (including the investigational treatment) within 180 days prior to screening visit
10. Participants who have received convalescent COVID-19 plasma treatment
11. Participants who have participated, within the last 30 days, in a clinical study involving an investigational intervention. If the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed
12.Participants who are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
13. Female who is pregnant or breast-feeding or plan to be pregnant within this study period
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1
|
JT001 administered orally in tablet form every 12 hours for 5 days (10 doses total)
Other Names:
|
Placebo Comparator: Arm 2
|
Placebo matching JT001 administered orally in tablet form every 12 hours for 5 days (10 doses total)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
progression of COVID-19:defined as progress to severe/critical COVID-19 or death from any cause
Time Frame: Up to 28 days
|
|
Up to 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall participant clinical status
Time Frame: Up to 28 days
|
Percentage of participants who experience these events by Day 28
|
Up to 28 days
|
COVID-19-related hospitalization rate of non-hospitalized participants
Time Frame: Up to 28 days
|
Percentage of participants who experience COVID-19-related hospitalization by Day 28
|
Up to 28 days
|
SARS-CoV-2 negative rate through Day7
Time Frame: Baseline through Day 7
|
Percentage of participants who achieve SARS-CoV-2 negative at Day 5 and 7
|
Baseline through Day 7
|
The plasma concentration
Time Frame: Baseline through Day 5
|
The plasma concentration of JT001 (VV116) and major metabolites
|
Baseline through Day 5
|
Safety assessments
Time Frame: Up to 28 days
|
Safety assessments such as AEs and SAEs
|
Up to 28 days
|
SARS-CoV-2 viral load
Time Frame: Baseline through Day 7
|
The SARS-CoV-2 viral load change from baseline to Day 5 and 7
|
Baseline through Day 7
|
SARS-CoV-2 viral load
Time Frame: Baseline through Day 7
|
SARS-CoV-2 viral load area under the response time curve (AUC) assessed through Day 7
|
Baseline through Day 7
|
To assess SARS-CoV-2 viral genetic variation
Time Frame: Day 1
|
SARS-CoV-2 viral genetic variation
|
Day 1
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Juan Ma, Medical Director, Shanghai JunTop Biosciences Co., LTD
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- JT001-004-II/III-COVID-19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mild to Moderate COVID-19
-
Károli Gáspár University of the Reformed Church...University of TorontoCompletedMild to Moderate Psychopathological SymptomsHungary
-
Károli Gáspár University of the Reformed Church...University of TorontoCompletedMild to Moderate Psychopathological SymptomsHungary
-
NestléCompletedMild to Moderate Levels of StressSwitzerland
-
Tishreen UniversityCompletedMild to Moderate Anterior Mandibular Segment CrowdindSyrian Arab Republic
-
Westlake Pharmaceuticals (Hangzhou) Co., Ltd.RecruitingMild to Moderate COVID-19China
-
Ology BioservicesPharm-Olam, LLC; Chemical, Biological, Radiological, and Nuclear MedicalWithdrawnMild to Moderate COVID-19
-
Kaleido BiosciencesCompletedMild-to-Moderate COVID-19United States
-
Kaleido BiosciencesCompletedMild-to-moderate COVID-19United States
-
Beer, Kenneth R., M.D., PAMedicis Pharmaceutical CorporationCompletedMild to Moderate Temporal Atrophy | Moderate to Severe Glabellar Rhytids | Moderate to Severe Periorbital RhytidsUnited States
-
Daewoong Pharmaceutical Co. LTD.TerminatedMild to Moderate COVID-19Korea, Republic of
Clinical Trials on JT001
-
Shanghai Vinnerna Biosciences Co., Ltd.Withdrawn
-
Shanghai Vinnerna Biosciences Co., Ltd.Sponsor GmbHCompleted
-
Shanghai Vinnerna Biosciences Co., Ltd.Sponsor GmbHRecruiting
-
Shanghai Vinnerna Biosciences Co., Ltd.Recruiting
-
Shanghai Vinnerna Biosciences Co., Ltd.Sponsor GmbHCompletedElderly Subjects With Underlying DiseasesChina
-
Shanghai Vinnerna Biosciences Co., Ltd.Sponsor GmbHTerminatedModerate to Severe COVID-19China, Uzbekistan
-
Shanghai Vinnerna Biosciences Co., Ltd.Sponsor GmbHCompletedSubjects With Liver Function Injury | Normal Liver Function SubjectChina
-
Vigonvita Life SciencesCompleted